Sangamo Therapeutics(us:SGMO)
0.5701
-13.07%
Updated on 2025-04-02
Open:0.6700
Close:0.5701
High:0.6700
Low:0.5463
Prev Close:0.6558
Volume:13.77M
Turnover:8.15M
Turnover Ratio:6.13%
Shares:224.71M
MarketCap:128.11M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 153 | 86785573 | 41.68% | 24 | 33 | 72 |
| 2024-03-31 | 148 | 100948854 | 49.56% | 21 | 30 | 68 |
| 2023-12-31 | 154 | 86932498 | 48.80% | 20 | 42 | 67 |
| 2023-09-30 | 158 | 102248899 | 57.68% | 10 | 34 | 74 |
| 2023-06-30 | 196 | 105766333 | 59.73% | 20 | 47 | 92 |
| 2023-03-31 | 193 | 111985479 | 65.19% | 21 | 73 | 59 |
| 2022-12-31 | 206 | 103803080 | 62.23% | 14 | 62 | 90 |
| 2022-09-30 | 214 | 97242601 | 60.06% | 29 | 66 | 70 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Wasatch Advisors Lp | 20132324 | 9.88% | 7734400 | 62.39% |
| 2024-03-31 | Armistice Capital, Llc | 16958477 | 8.33% | 16958477 | |
| 2024-03-31 | Blackrock Inc. | 13277637 | 6.52% | -818228 | -5.80% |
| 2024-03-31 | Vanguard Group Inc | 12200368 | 5.99% | -398761 | -3.16% |
| 2024-03-31 | Acadian Asset Management Llc | 4943260 | 2.43% | 192385 | 4.05% |
| 2024-03-31 | Geode Capital Management, Llc | 3363791 | 1.65% | 157481 | 4.91% |
| 2024-03-31 | D. E. Shaw & Co., Inc. | 3067435 | 1.51% | -1616538 | -34.51% |
| 2024-03-31 | State Street Corp | 2751804 | 1.35% | 43436 | 1.60% |
| 2024-03-31 | Renaissance Technologies Llc | 2597977 | 1.28% | -547901 | -17.42% |
| 2024-03-31 | Two Sigma Advisers, Lp | 1428255 | 0.70% | -657000 | -31.51% |
About
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
Address:501 Canal Boulevard
Website:http://www.sangamo.com
Market Movers